Effective analgesia for rats frequently includes standard buprenorphine, a partial mu-opioid agonist lasting 6-8 hrs. Novel, longer-acting buprenorphine preparations are available; however, investigations concerning physiologic (antinociception, thermoregulatory, etc.) and behavioral (food intake, pica behavior, etc.) effects in rats are sparse. The objective was to investigate physiology and behavior associated with new buprenorphine formulations in rats. Ethiqa XR® (0.65 mg/kg SC; Fidelis Pharmaceuticals, LLC), Zorbium® (10 mg/kg transdermal; Elanco), and appropriate controls were given to male rats in a randomized, blinded, cross-over design. Thermal antinociception, body temperature, food/kaolin intake, and fecal output were measured 1-72 hrs post-treatment. Kaolin is a clay substance used to test pica behavior. Overall antinociception with both buprenorphine treatments differed from the control treatment (p<0.05). Body temperatures were elevated with both buprenorphine treatments from 4-24 hrs (p<0.05). Food intake in the dark period was decreased from 24-72 hrs and fecal output reduced in both light/dark periods for 24 hrs following both preparations (p<0.05); kaolin intake (pica behavior) did not differ between treatments (p>0.05). Self-aggression was noted with both buprenorphine treatments from 4-12 hrs and sedation was associated with Zorbium between 12 and 24 hrs (p<0.05). This study provides evidence that newer, long-acting buprenorphine preparations may provide analgesia for both client owned and laboratory rats, but untoward physiologic effects need to be considered.